Cyclacel Phar Pr Stock Price, News & Analysis

Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported Q1 2025 financial results and announced strategic changes. The company will now focus solely on developing plogosertib (plogo), having repurchased related assets for $0.3M. Following the liquidation of UK subsidiary Cyclacel Limited on January 31, 2025, the company deconsolidated its financials, resulting in a $5.0M gain in stockholders' equity. Due to funding challenges, Cyclacel entered an Exchange Agreement with FITTERS Diversified Berhad, exchanging shares for approximately 19.99% ownership to acquire Fitters Sdn. Bhd., a Malaysian fire safety equipment company. Q1 2025 financials show cash position of $3.5M, reduced R&D expenses of $0.8M (vs $2.8M in Q1 2024), increased G&A expenses of $4.2M, and a minimal net loss of $0.1M. Current cash is expected to fund operations into Q2 2025.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.

Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire its subsidiary, Fitters Sdn. Bhd., through a share exchange transaction. Under the agreement, Cyclacel will issue common stock representing 19.99% of its outstanding shares to FITTERS, while existing Cyclacel stockholders will retain approximately 80.01% ownership of the combined company.

Post-transaction, Cyclacel will be renamed to Bio Green Med Solution, Inc. and will continue trading on Nasdaq under a new ticker symbol. The deal must close by August 31, 2025, and requires approval from both companies' stockholders. The transaction has already received unanimous approval from the Boards of Directors of all involved entities. No officers or directors from FITTERS or Fitters Sub will be appointed to Cyclacel.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced its Q4 2024 financial results and strategic updates. The company is streamlining operations to focus on developing plogosertib, a PLK 1 inhibitor for advanced cancers, following its acquisition from Cyclacel on March 10, 2025.

Financial highlights include:

• Pro forma cash and equivalents of $7.2M as of Dec 31, 2024
• R&D expenses decreased to $6.7M in 2024 from $19.2M in 2023
• Net loss reduced to $11.2M in 2024 from $22.6M in 2023
• Current cash expected to fund operations into Q2 2025

The liquidation of Cyclacel is expected to increase stockholders' equity by approximately $5.0M and significantly reduce R&D expenses in 2025. The company is developing a new oral formulation of plogosertib with improved bioavailability.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has secured $1.0 million through a private placement of convertible Series E Preferred Stock to accredited investors, completed on March 21, 2025. Each preferred share is convertible into 110 common shares, subject to stockholder approval per Nasdaq rules.

The company plans to use the net proceeds for working capital and general corporate purposes. Combined with existing cash reserves, this financing is expected to extend Cyclacel's cash runway into the third quarter of 2025. Preferred stockholders will be entitled to participate in any dividends declared on common stock on an as-converted basis.

The securities were issued under Regulation S of the Securities Act and were offered directly to investors without intermediaries. Arc Group and Rimon P.C. served as financial advisor and legal counsel, respectively.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced a significant change in control and leadership on February 26, 2025. Datuk Dr. Doris Wong Sing Ee acquired controlling interest through the purchase of convertible preferred stock from former interim CEO David Lazar for $6.3 million.

The transaction involved 1,000,000 shares of Series C and 1,745,262 shares of Series D Convertible Preferred Stock, which were converted into 2,650,000 and 191,978,820 common shares respectively. This resulted in the purchaser owning 70% of Cyclacel's outstanding shares.

Following the transaction, significant leadership changes occurred: David Lazar resigned as interim CEO, Datuk Dr. Doris Wong Sing Ee became CEO and Executive Director, and Kiu Cu Seng was appointed as Executive Director, Secretary and CFO. Additionally, multiple board members resigned or provided notice of resignation, with Chong Kwang Fock joining as an Independent Director.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) has entered into a securities purchase agreement with investor David Lazar, who will invest $3.1 million through the purchase of convertible preferred stock. The deal includes 1,000,000 shares of Series C Preferred Stock at $1.00 per share (convertible to 2.65 common shares each) and 2,100,000 shares of Series D Preferred Stock (convertible to 110 common shares each).

As part of the agreement, significant board changes were announced, with David Lazar appointed as interim CEO, replacing Spiro Rombotis. The company also entered into a Warrant Exchange Agreement to exchange warrants for 24,844,725 common shares plus $1.1 million in cash.

The company must obtain stockholder approval for both the preferred stock conversion and warrant exchange. Cyclacel faces a February 6, 2025 deadline to comply with Nasdaq's minimum stockholders' equity requirement to avoid potential delisting. Management has been directed to reduce operating costs while exploring strategic alternatives.

Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced it is exploring strategic alternatives to preserve cash, including a potential transaction with investor David Lazar of Activist Investing, , subject to existing securityholder consent. The company's Board is reviewing strategies to realize value from assets and has directed management to reduce operating costs.

The company currently does not meet Nasdaq's continued listing requirements and faces potential delisting if compliance is not regained. Without securing a strategic transaction or additional funding, Cyclacel may be forced to cease operations, potentially resulting in stockholders losing part or all of their investment.

Cyclacel Pharmaceuticals announced the closing of a warrant exercise transaction, raising $2.1 million in gross proceeds. The company facilitated the exercise of existing warrants for 4,968,945 shares at a reduced price of $0.415 per share, down from the original $1.36. In exchange, Cyclacel issued new unregistered Series C and D warrants, each for 9,937,890 shares at $0.415 per share. The Series C warrants have a 5.5-year term, while Series D warrants expire in 18 months, both pending stockholder approval. The proceeds will be used for working capital and general corporate purposes.